All stock lists
Fulgent Genetics, Inc. (NASDAQ:FLGT)
US · Delayed Price · Currency is USD
Healthcare · Medical - Diagnostics & Research
20.41+0.32 (+1.57%)
Insider Score
––Not scored
FLGT Insider Score
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
FLGT Income Statement
| Fiscal Period | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 |
|---|---|---|---|---|---|---|
| Period Ending | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 |
| Revenue | 85.39 M | 71.14 M | 83.34 M | 84.07 M | 81.80 M | 73.46 M |
| Revenue Growth (YoY) | 4.38 % | -3.16 % | 9.34 % | 17.18 % | 15.17 % | 13.92 % |
| Cost of Revenue | 59.71 M | 49.65 M | 50.75 M | 48.56 M | 47.37 M | 45.12 M |
| Gross Profit | 25.68 M | 21.49 M | 32.58 M | 35.51 M | 34.44 M | 28.35 M |
| SG&A Expense | 42.42 M | 39.91 M | 52.62 M | 34.98 M | 38.68 M | 33.76 M |
| R&D Expense | 14.55 M | 14.18 M | 14.17 M | 13.86 M | 13.48 M | 12.39 M |
| Operating Expenses | 59.58 M | 56.11 M | 68.82 M | 50.86 M | 54.15 M | 48.14 M |
| Operating Income | -33.90 M | -34.62 M | -36.24 M | -15.35 M | -19.71 M | -19.80 M |
| Pretax Income | -29.69 M | -25.98 M | -29.27 M | -6.14 M | -21.52 M | -11.72 M |
| Tax Provision | 29.00 K | -704.00 K | -5.62 M | 683.00 K | -2.26 M | 176.00 K |
| Net Income | -29.53 M | -24.83 M | -23.42 M | -6.61 M | -18.96 M | -11.53 M |
| EPS (Basic) | -1.05 | -0.80 | -0.76 | -0.21 | -0.61 | -0.37 |
| EPS (Diluted) | -1.05 | -0.80 | -0.76 | -0.21 | -0.61 | -0.37 |
| Shares Outstanding | 28.00 M | 30.88 M | 30.78 M | 30.75 M | 30.83 M | 30.83 M |
Quarterly figures; YoY compares the same fiscal quarter a year earlier. Source: public market data.
Disclaimer — Informational only — not investment advice. Insider transaction data is sourced from SEC Form 4 filings; market data from public feeds and may be delayed. The Insider Score is a proprietary score for research purposes and does not predict future performance. Always do your own research.